Jane Huang, CMO, Hematology at BeiGene, holds 160.06K shares in BeiGene (Ticker: BGNE), holds ― shares in Protara Therapeutics (Ticker: TARA), holds 51.29K shares in Prelude Therapeutics (Ticker: PRLD).

See the Hottest Stocks Based on Insider Trading >

Jane Huang
BeiGene (BGNE)
CMO, Hematology

Ranked #4,978 out of 98,624 Corporate Insiders

Profitable Transactions

28 out of 44 Profitable Transactions

Average Return

+10.70%

Average return per transaction

Time Frame

1 Year

Compare to

No Benchmark

How are Insiders Ranked?

Insider Holdings

99.24%

BGNE

0.76%

PRLD

0.00%

TARA

A breakdown of Jane Huang's holdings

See the Top Stocks by Insiders

Insider Roles

BeiGene
(BGNE)

CMO, Hematology

Prelude Therapeutics
(PRLD)

President, CMO

Protara Therapeutics
(TARA)

Director

Roles that Jane Huang holds in companies

See the Top Corporate Insiders

Most Profitable Insider Trade

Stock:

BeiGene
(BGNE)

Rating:Informative Buy

Date:Jun 30, 2020 - Jun 30, 2021

Return:+89.30%

The most profitable trade made by Jane Huang

See the Latest Stocks Traded by Insiders

Jane Huang's Trading History

BGNE

BeiGene

Dec 16, 2021

CMO, Hematology

Uninformative Sell

417.21K

$25.97M

TARA

Protara Therapeutics

―

Director

―

PRLD

Prelude Therapeutics

Apr 08, 2024

President, CMO

Uninformative Buy

15.86K

$197.97K

List of latest transactions for each holding click on a transaction to see Jane Huang's performance on stock

See All Insider Trading from Today

Jane Huang insider profile FAQ

What is the percentage of profitable transactions made by Jane Huang?

The percentage of profitable transactions made by Jane Huang is 64%.

What is the average return per transaction made by Jane Huang?

The average return per transaction made by Jane Huang is 10.70%.

What stocks does Jane Huang hold?

Jane Huang holds: BGNE, TARA, PRLD stocks.

What was Jane Huang’s latest transaction?

Jane Huang latest transaction was an Uninformative Sell of $417.21K.

What was Jane Huang's most profitable transaction?

Jane Huang’s most profitable transaction was an Informative Buy of BGNE stock on June 30, 2020. The return on the trade was 89.30%.

What is Jane Huang's role in BeiGene?

Jane Huang's role in BeiGene is CMO, Hematology.

How can I follow the stock ratings of top corporate insiders?

Head over to our Expert Center to see a list of the Top 100 corporate insiders and follow the corporate insiders of your choice. Visit their profiles for more details about their stock transactions and see how they perform on a stock-by-stock basis.

Jane Huang Insider Profile

Jane Huang BeiGene (BGNE)CMO, Hematology